Comparative Pharmacology
Head-to-head clinical analysis: VALRUBICIN versus VALSTAR PRESERVATIVE FREE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VALRUBICIN versus VALSTAR PRESERVATIVE FREE.
VALRUBICIN vs VALSTAR PRESERVATIVE FREE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Anthracycline topoisomerase II inhibitor and DNA intercalator, causing DNA damage and cell death.
Valrubicin is a semisynthetic anthracycline derivative that intercalates into DNA, inhibiting nucleic acid synthesis and inducing cell death. It is cytotoxic to both dividing and non-dividing cells.
Intravesical instillation: 800 mg (4 vials of 200 mg/5 mL) diluted in 25 mL of 0.9% Sodium Chloride Injection, instilled into the bladder once weekly for 6 weeks. Retain in bladder for 1-2 hours.
Intravesical instillation of 800 mg (40 mL of 20 mg/mL solution) weekly for 6 weeks, retained in bladder for 2 hours.
None Documented
None Documented
Terminal half-life is approximately 38 hours; clinically, it supports every-3-week dosing to avoid accumulation.
Clinical Note
moderateValrubicin + Digoxin
"Valrubicin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateValrubicin + Digitoxin
"Valrubicin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateValrubicin + Deslanoside
"Valrubicin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateValrubicin + Acetyldigitoxin
"Valrubicin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 3-5 hours; clinical context: supports intravesical instillation with minimal systemic absorption.
Primarily hepatic metabolism and biliary excretion; renal excretion accounts for <5% of unchanged drug.
Renal: approximately 50-70% excreted unchanged in urine within 72 hours; biliary/fecal: minor (<5%).
Category C
Category C
Anthracycline Antineoplastic
Anthracycline Antineoplastic